Ventricular Assist Devices Market Set for Strong Growth at 10% CAGR by 2031, Led by North America's 58% Global Market Share | DataM Intelligence

The Global Ventricular Assist Devices (VADs) Market is projected to grow at a strong CAGR of 10% during the forecast period 2024-2031.

Market growth is fueled by the rising prevalence of heart failure, increasing adoption of mechanical circulatory support devices, and advancements in miniaturized, durable VAD technologies. Furthermore, a growing aging population, improved survival rates post-cardiac surgeries, and expanding use of VADs as both bridge-to-transplant and destination therapy are contributing to sustained market momentum.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/ventricular-assist-devices-market?ram

United States: Key Industry Developments

✅ June 2025: FDA granted breakthrough device status to BiVACOR's totally implantable artificial heart, accelerating U.S. clinical trial timelines for advanced ventricular assist support in heart failure patients.

✅ April 2025: CARMAT received conditional FDA approval for the second cohort of its Aeson artificial heart feasibility study, advancing implantable options for severe heart failure cases.

✅ March 2025: Cadrenal Therapeutics and Abbott launched the TECH-LVAD trial to assess tecarfarin anticoagulation in HeartMate 3 ventricular assist device recipients, aiming to improve long-term outcomes.

Asia Pacific / Japan: Key Industry Developments

✅ June 2025: Japan's Pharmaceuticals and Medical Devices Agency (PMDA) introduced adaptive regulatory frameworks, enabling faster access to innovative ventricular assist devices amid rising cardiovascular disease cases.

Key Merges and Acquisitions(2025):
✅ Abbott receives FDA clearance for next-generation HeartMate 3: In December 2025, Abbott received a U.S. FDA clearance for software enhancements and minor hardware improvements to its market-leading HeartMate 3 Left Ventricular Assist System (LVAS), focusing on improved data logging and remote monitoring capabilities.

✅ LivaNova reports strong Q3 performance in neuromodulation and potential for VAD investment: In its October 2025 earnings call, LivaNova reported strong growth, providing capital for R&D in other strategic areas, including potential future investments or partnerships in the VAD space.

✅ Koninklijke Philips N.V. secures U.S. government contract: In November 2025, Philips secured a significant contract with a U.S. government agency for AEDs. This large-scale government procurement highlights the strong market position of major medtech players and a reliable revenue stream that supports R&D in other areas like VADs.

Market Segmentation Analysis:
-By Product Type: LVADs Dominate
Left Ventricular Assist Devices (LVADs) lead with 48.2% market share in 2024, driven by high adoption in end-stage heart failure patients and technological advancements improving survival rates.​
Right Ventricular Assist Devices (RVADs) and Biventricular Assist Devices (BIVADs) hold smaller shares, used for specific right-heart or dual-ventricle support in complex cases.​

-By Design: Implantables Command Majority
Implantable Ventricular Assist Devices hold the largest share, valued at $2 billion in 2024, fueled by innovations in efficiency and reliability for long-term heart failure treatment.​
Transcutaneous Ventricular Assist Devices serve shorter-term needs with external components, representing the smaller segment due to limited durability.​

-By Application: Destination Therapy Leads
Destination Therapy dominates, growing at 8.9% CAGR, as a permanent solution for ineligible transplant patients amid rising heart failure prevalence.​
Bridge-to-Transplant (BTT) follows as the former revenue leader, supporting patients awaiting donors; Bridge-to-Candidacy and Bridge-to-Recovery target recovery or evaluation phases.​

-By End-User: Hospitals Prevail
Hospitals command 43.1% share, projected to reach $2.4 billion, due to advanced infrastructure for VAD implantation and monitoring.​
Ambulatory Surgical Centers, Specialty Clinics, and Others grow via outpatient procedures but trail hospitals in scale.​

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=ventricular-assist-devices-market?ram (Purchase 2 or more Reports and get 50% Discount)

Growth Drivers:
-Rising prevalence of heart failure and cardiovascular diseases worldwide drives demand for ventricular assist devices as effective support therapies.​

-Expanding geriatric population increases susceptibility to end-stage heart failure, boosting adoption of these life-sustaining devices.​

-Technological advancements, such as miniaturized continuous-flow pumps and magnetically levitated designs, improve patient outcomes and reduce complications like thrombosis.​

-Growing use in bridge-to-transplant and destination therapy applications expands market accessibility amid organ shortages.​

-Increased healthcare investments, favorable policies, and infrastructure improvements in regions like Asia Pacific and North America accelerate device penetration.

Regional Insights:
-North America commands the largest share of the Ventricular Assist Devices (VAD) market at approximately 58%, driven by advanced healthcare infrastructure, high prevalence of heart failure, robust R&D investments, and favorable reimbursement policies, particularly in the US which dominates regionally.​

-Europe follows with a notable but smaller market presence, supported by established cardiac care systems and ongoing clinical trials, though specific share figures trail behind North America amid varying adoption rates across countries like the UK.​

-Asia Pacific holds a growing yet comparatively lower share, fueled by rising cardiovascular cases, aging populations, and expanding healthcare access in nations like China, positioning it for the fastest future growth despite current lower dominance.​

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/ventricular-assist-devices-market?ram

Key Players:
Abbott Laboratories | Abiomed Inc | Berlin Heart GmbH | Medtronic Plc | Jarvik Heart Inc | EVAHEART Inc | Cirtec | CorWave SA | Calon Cardio-Technology Ltd | Teleflex Incorporated

Key Highlights (Top 5 Key Players) for Ventricular Assist Devices Market:
-Abbott Laboratories leads the market with its HeartMate 3 platform capturing a dominant share of global revenues alongside Medtronic and Johnson & Johnson, which together hold roughly 60% of the sector.​

-Medtronic Plc drives growth through its Impella catheter-based pumps for percutaneous support, strengthening its position in the concentrated competitive landscape.​

-Abiomed Inc., part of Johnson & Johnson, bolsters market leadership via acquisitions like V-Wave to expand heart failure solutions amid high R&D barriers.​

-Berlin Heart GmbH remains a key contender in the ventricular assist devices space, focusing on advanced implantation technologies for heart failure patients.​

-Jarvik Heart, Inc. contributes to innovation in next-generation devices, supporting overall market expansion projected at 8-11% CAGR through 2030-2033.​

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.